×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SVRA – savara, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SVRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
12/20
08:16 am
svra
Savara Inc (NASDAQ: SVRA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $8.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $8.00 price target on the stock.
12/19
10:24 am
svra
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
12/18
04:17 pm
svra
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Medium
Report
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
12/18
04:05 pm
svra
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Medium
Report
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
12/17
04:05 pm
svra
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
11/25
09:40 am
svra
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA) [Yahoo! Finance]
Low
Report
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA) [Yahoo! Finance]
11/22
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
12/19
10:24 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
Report
-0.5%
12/19
10:24 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
Report
-0.5%
12/19
10:18 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
Report
-0.5%
Date
Time
Symbol
Headline
Impact
12/16
06:11 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Erickson Anne
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Erickson Anne
12/16
06:08 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Parker Braden C.
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Parker Braden C.
12/16
06:05 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Lutz Robert Matthew
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Lutz Robert Matthew
12/16
06:00 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Lowrance David L
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Lowrance David L
12/16
05:58 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Pratt Raymond Dennis
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Pratt Raymond Dennis
12/16
05:57 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Pauls Matthew
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Pauls Matthew
12/16
05:54 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Hawkins Richard J
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Hawkins Richard J
12/16
05:51 pm
svra
Form 4 Savara Inc For: Dec 12 Filed by: Elam Nevan C
Low
Report
Form 4 Savara Inc For: Dec 12 Filed by: Elam Nevan C
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/30
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
180.6%
11/15 Form 8-K Savara Inc For: Nov 15 21.1%
11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%
12/20 Form 8-K Savara Inc For: Dec 20 15.1%
6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%
12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%
3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%
10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%
3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%
4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%
11/15 Form 8-K Savara Inc For: Nov 15 21.1%
11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%
12/20 Form 8-K Savara Inc For: Dec 20 15.1%
6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%
12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%
3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%
10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%
3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%
4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%
TOP News Decliners
10/2
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
-58.5%
3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%
2/3 Form 8-K Savara Inc For: Jan 31 -15.8%
4/2 Form 8-K Savara Inc For: Mar 31 -14.3%
12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%
3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%
3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%
12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%
6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%
3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%
2/3 Form 8-K Savara Inc For: Jan 31 -15.8%
4/2 Form 8-K Savara Inc For: Mar 31 -14.3%
12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%
3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%
3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%
12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%
6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: